Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 99.76% | -92.31% | 39.78% | -41.15% | 16.67% |
| Total Depreciation and Amortization | -2.70% | -5.13% | 3.31% | -3.82% | 3.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -131.62% | 303.45% | -45.28% | 115.45% | 355.56% |
| Change in Net Operating Assets | 50.00% | -231.51% | -217.39% | 88.83% | 50.12% |
| Cash from Operations | -346.97% | 842.86% | -73.08% | 113.98% | 66.00% |
| Capital Expenditure | -47.22% | -2.86% | 32.69% | 22.39% | 33.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -30.43% | -204.55% | 283.33% | -200.00% | 80.00% |
| Cash from Investing | -40.68% | -178.67% | 217.19% | 9.86% | 40.83% |
| Total Debt Issued | 100.00% | 0.00% | 0.00% | -66.67% | 50.00% |
| Total Debt Repaid | -5.10% | 2.49% | 0.00% | 66.56% | -49.88% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -383.33% | 60.00% | -500.00% | 94.25% | -480.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 547.62% | 167.74% | -229.17% | 127.27% | -107.22% |
| Foreign Exchange rate Adjustments | 114.29% | -158.33% | 271.43% | 12.50% | -214.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | -- | -- |
| Net Change in Cash | -619.05% | -75.58% | 295.45% | 87.54% | -163.15% |